ArticleFrontiers in pediatrics2025
Effectiveness of adjunctive Xiao-er Kechuanling to terbutaline and montelukast in children with uncontrolled asthma: a prospective observational cohort study.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Achieving optimal control in childhood asthma remains challenging, particularly with therapies like short-acting beta2-agonists (SABA) plus leukotriene receptor antagonists (LTRA). Xiao-er Kechuanling (XKL), a traditional Chinese medicine formula with demonstrated anti-inflammatory and bronchodilatory effects, presents a potential adjunctive therapy. This study aimed to compare the clinical effectiveness and safety of adjunctive XKL added to terbutaline (SABA) and montelukast (LTRA) (Triple Therapy) vs. terbutaline plus montelukast alone (Dual Therapy) in children with uncontrolled asthma. Methods: This single-center, prospective observational cohort study enrolled children aged 6-14 years with uncontrolled asthma (ACT ≤ 19) receiving either Dual or Triple Therapy based on physician prescription, with no inhaled corticosteroid use for ≥3 months prior. Participants were followed for 6 months. Primary outcomes included the proportion achieving ≥3-point ACT score increase, severe exacerbation frequency, and changes in serum (TGF-β1, MMP-9/TIMP-1 ratio) and HRCT (WT/D ratio) remodeling markers. Secondary outcomes included lung function (FEV1/FVC, PEF variability), inflammatory markers (IL-4, IL-13, ECP), and safety. Results: 199 children were enrolled (95 Dual, 104 Triple); 94 Dual and 88 Triple completed the 6-month follow-up. Baseline characteristics were comparable between groups ( Conclusion: In this observational study, adding XKL to terbutaline and montelukast was associated with significant improvements in asthma control, lung function, and markers of inflammation and airway remodeling in children with uncontrolled asthma over 6 months, with a comparable safety profile. However, due to the observational design and lack of confounder adjustment, these findings indicate association, not causality. Randomized controlled trials are needed to confirm the effectiveness of this adjunctive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.